Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Table 2 Day 85 trough FEV₁ (mL) by patient subgroup

Subgroups	Revefenacin 175 μg (n = 395)	Placebo (n = 417)
ITT
Evaluable n	310	296
LS mean difference (95% CI)	148.1 (115.2, 181.1); p < 0.0001
FEV₁30%–< 50% pred
Evaluable n	101	78
LS mean difference (95% CI)	131.2 (70.7, 191.6), p < 0.0001
FEV₁ < 30% pred
Evaluable n	17	9
LS mean difference (95% CI)	176.2 (14.7, 337.5), p = 0.0324
2011 GOLD category D
Evaluable n	108	83
LS mean difference (95% CI)	124.6 (66.5, 182.7), p < 0.0001
ICS use
Evaluable n	135	108
LS mean difference (95% CI)	130.6 (78.7, 182.5), p < 0.001
LABA or ICS/LABA use
Evaluable n	118	89
LS mean difference (95% CI)	139.2 (82.9, 195.5), p < 0.0001
> 65 years
Evaluable n	143	128
LS mean difference (95% CI)	140.3 (91.0, 189.7), p < 0.0001
> 75 years
Evaluable n	28	25
LS mean difference (95% CI)	129.2 (18.9, 239.5), p = 0.0217
Reversible to ipratropium and albuterol
Evaluable n	70	57
LS mean difference (95% CI)	286.5 (214.8, 358.2), p < 0.0001
History of CV disease
Evaluable n	21	27
LS mean difference (95% CI)	140.7 (18.4, 263.0), p = 0.0242
History of diabetes
Evaluable n	85	57
LS mean difference (95% CI)	101.6 (27.0, 176.3), p = 0.0077
History of cognitive/mental impairments
Evaluable n	45	44
LS mean difference (95% CI)	149.5 (64.5, 234.5), p = 0.0006

CI confidence intervals; CV cardiovascular; FEV₁ forced expiratory volume in 1 s; GOLD Global Initiative for Chronic Obstructive Lung Disease, LABA long-acting ß agonist; ICS inhaled corticosteroids; ITT intention-to-treat; pred predicted

ISSN: 1471-2466